{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:06:29Z","timestamp":1793862389367,"version":"4.6.1"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Cancer patients undergoing chemotherapy often experience very debilitating side effects, including unintentional weight loss, nausea, and vomiting. Changes in body composition, specifically lean body mass (LBM), are known to have important implications for anticancer drug toxicity and cancer prognosis. Currently, chemotherapy dosing is based on calculation of body surface area, although this approximation does not take into consideration the variability in lean and adipose tissue mass.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Patients with depletion of muscle mass present higher chemotherapy-related toxicity, whereas patients with larger amounts of LBM show fewer toxicities and better outcomes. Commonly used chemotherapy regimens promote changes in body composition, primarily by affecting skeletal muscle, as well as fat and bone mass. Experimental evidence has shown that pro-atrophy mechanisms, abnormal mitochondrial metabolism, and reduced protein anabolism are primarily implicated in muscle depletion. Muscle-targeted pro-anabolic strategies have proven successful in preserving lean tissue in the occurrence of cancer or following chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Muscle wasting often occurs as a consequence of anticancer treatments and is indicative of worse outcomes and poor quality of life in cancer patients. Accurate assessment of body composition and preservation of muscle mass may reduce chemotherapy toxicity and improve the overall survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/spc.0000000000000382","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T13:16:26Z","timestamp":1534511786000},"page":"420-426","source":"Crossref","is-referenced-by-count":178,"title":["Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition"],"prefix":"10.1097","volume":"12","author":[{"given":"Fabrizio","family":"Pin","sequence":"first","affiliation":[{"name":"Department of Anatomy and Cell Biology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion E.","family":"Couch","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head & Neck Surgery"},{"name":"Center for Cachexia Research Innovation and Therapy"},{"name":"Simon Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bonetto","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell Biology"},{"name":"Department of Otolaryngology \u2013 Head & Neck Surgery"},{"name":"Center for Cachexia Research Innovation and Therapy"},{"name":"Simon Cancer Center"},{"name":"Department of Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230926","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fphar.2013.00068","article-title":"Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy","volume":"4","author":"Crawford","year":"2013","journal-title":"Front Pharmacol"},{"key":"R2-20230926","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.20777","article-title":"The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer","volume":"103","author":"Brown","year":"2005","journal-title":"Cancer"},{"key":"R3-20230926","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/pcan.2008.51","article-title":"Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation","volume":"12","author":"Galvao","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R4-20230926","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-005-5991-z","article-title":"Objective and subjective upper body function six months following diagnosis of breast cancer","volume":"94","author":"Hayes","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"R5-20230926","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1200\/JCO.2001.19.13.3226","article-title":"Late medical complications and fatigue in Hodgkin's disease survivors","volume":"19","author":"Knobel","year":"2001","journal-title":"J Clin Oncol"},{"key":"R6-20230926","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1188\/09.ONF.194-202","article-title":"Fatigue and physical activity in older patients with cancer: a six-month follow-up study","volume":"36","author":"Luctkar-Flude","year":"2009","journal-title":"Oncol Nurs Forum"},{"key":"R7-20230926","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11136-007-9215-3","article-title":"Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report","volume":"16","author":"Meeske","year":"2007","journal-title":"Qual Life Res"},{"key":"R8-20230926","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1002\/cncr.26226","article-title":"Prolonged impact of chemotherapy on fatigue in breast cancer survivors: a longitudinal comparison with radiotherapy-treated breast cancer survivors and noncancer controls","volume":"118","author":"Goedendorp","year":"2012","journal-title":"Cancer"},{"key":"R9-20230926","doi-asserted-by":"crossref","first-page":"43442","DOI":"10.18632\/oncotarget.9779","article-title":"Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1\/2 and p38 MAPKs","volume":"7","author":"Barreto","year":"2016","journal-title":"Oncotarget"},{"key":"R10-20230926","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00000421-199808000-00007","article-title":"Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma","volume":"21","author":"Rosenthal","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"R11-20230926","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3912\/OJIN.Vol8No01HirshPsy02","article-title":"Cancer-related fatigue","volume":"8","author":"Visovsky","year":"2003","journal-title":"Online J Issues Nurs"},{"key":"R12-20230926","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrclinonc.2012.99","article-title":"Reducing the toxicity of cancer therapy: recognizing needs, taking action","volume":"9","author":"Cleeland","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"R13-20230926","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nrclinonc.2012.88","article-title":"Translational approaches to treatment-induced symptoms in cancer patients","volume":"9","author":"Dantzer","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"R14-20230926","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.5-5-353","article-title":"Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition","volume":"5","author":"Curt","year":"2000","journal-title":"Oncologist"},{"key":"R15-20230926","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF00364968","article-title":"Assessment of fatigue in cancer and noncancer patients and in healthy individuals","volume":"1","author":"Glaus","year":"1993","journal-title":"Support Care Cancer"},{"key":"R16-20230926","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0140-6736(03)14186-4","article-title":"Assessment and management of cancer-related fatigue in adults","volume":"362","author":"Ahlberg","year":"2003","journal-title":"Lancet"},{"key":"R17-20230926","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/cncr.11742","article-title":"Cancer-related fatigue: evolving concepts in evaluation and treatment","volume":"98","author":"Stasi","year":"2003","journal-title":"Cancer"},{"key":"R18-20230926","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/jcsm.12199","article-title":"Muscle mass as a target to reduce fatigue in patients with advanced cancer","volume":"8","author":"Neefjes","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R19-20230926","first-page":"9","article-title":"National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression, and fatigue, July 15\u201317, 2002","author":"Patrick","year":"2004","journal-title":"J Natl Cancer Inst Monogr"},{"key":"R20-20230926","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1164\/ajrccm\/142.2.474","article-title":"Respiratory muscle fatigue. Report of the Respiratory Muscle Fatigue Workshop Group","volume":"142","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"R21-20230926","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/cncr.22993","article-title":"Fatigue after treatment for early stage breast cancer: a controlled comparison","volume":"110","author":"Jacobsen","year":"2007","journal-title":"Cancer"},{"key":"R22-20230926","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpainsymman.2009.06.011","article-title":"Fatigue in gynecological cancer patients during and after anticancer treatment","volume":"39","author":"Prue","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"R23-20230926","first-page":"369","article-title":"Progress toward guidelines for the management of fatigue","volume":"12","author":"Cella","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"R24-20230926","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0885-3924(99)00082-2","article-title":"Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates","volume":"18","author":"Jacobsen","year":"1999","journal-title":"J Pain Symptom Manage"},{"key":"R25-20230926","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1188\/ONF.537-546","article-title":"Fatigue in patients with cancer","volume":"29","author":"Nail","year":"2002","journal-title":"Oncol Nurs Forum"},{"key":"R26-20230926","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1523-5394.2001.009003119.x","article-title":"Fatigue and quality of life outcomes of exercise during cancer treatment","volume":"9","author":"Mock","year":"2001","journal-title":"Cancer Pract"},{"key":"R27-20230926","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1477-7525-7-102","article-title":"Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008","volume":"7","author":"Montazeri","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"R28-20230926","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcsm.12165","article-title":"Muscle strength in breast cancer patients receiving different treatment regimes","volume":"8","author":"Klassen","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R29-20230926","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1186\/s12885-017-3562-4","article-title":"Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced nonsmall-cell lung cancer","volume":"17","author":"Naito","year":"2017","journal-title":"BMC cancer"},{"key":"R30-20230926","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition"},{"key":"R31-20230926","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0959-8049(02)00151-X","article-title":"Dosing strategies for anticancer drugs: the good, the bad and body-surface area","volume":"38","author":"Felici","year":"2002","journal-title":"Eur J Cancer"},{"key":"R32-20230926","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1200\/JCO.1998.16.7.2297","article-title":"Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?","volume":"16","author":"Ratain","year":"1998","journal-title":"J Clin Oncol"},{"key":"R33-20230926","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.clnu.2012.05.009","article-title":"Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results","volume":"32","author":"Thoresen","year":"2013","journal-title":"Clin Nutr"},{"key":"R34-20230926","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/bjc.2012.357","article-title":"Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents","volume":"107","author":"Chatelut","year":"2012","journal-title":"Br J Cancer"},{"key":"R35-20230926","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"R36-20230926","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","article-title":"Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity","volume":"13","author":"Prado","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R37-20230926","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/annonc\/mdp605","article-title":"Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma","volume":"21","author":"Antoun","year":"2010","journal-title":"Ann Oncol"},{"key":"R38-20230926","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1634\/theoncologist.2016-0066","article-title":"The prevalence and prognostic value of low muscle mass in cancer patients: a review of the literature","volume":"21","author":"Rier","year":"2016","journal-title":"Oncologist"},{"key":"R39-20230926","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.nut.2016.04.002","article-title":"A high visceral adipose tissue-to-skeletal muscle ratio as a determinant of major complications after pancreatoduodenectomy for cancer","volume":"32","author":"Sandini","year":"2016","journal-title":"Nutrition"},{"key":"R40-20230926","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/cam4.621","article-title":"Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens","volume":"5","author":"Ali","year":"2016","journal-title":"Cancer Med"},{"key":"R41-20230926","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index","volume":"31","author":"Martin","year":"2013","journal-title":"J Clin Oncology"},{"issue":"(Suppl 2)","key":"R42-20230926","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/annonc\/mdx810","article-title":"Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy","volume":"29","author":"Baracos","year":"2018","journal-title":"Ann Oncol"},{"key":"R43-20230926","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.clnu.2015.05.011","article-title":"Sarcopenic obesity: a probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients","volume":"35","author":"Anandavadivelan","year":"2016","journal-title":"Clin Nutr"},{"key":"R44-20230926","first-page":"491","article-title":"Low visceral fat content is a negative predictive marker for bevacizumab in metastatic colorectal cancer","volume":"38","author":"Miyamoto","year":"2018","journal-title":"Anticancer Res"},{"key":"R45-20230926","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1002\/cncr.30950","article-title":"Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: the C-SCANS study","volume":"123","author":"Cespedes Feliciano","year":"2017","journal-title":"Cancer"},{"key":"R46-20230926","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1245\/s10434-014-4281-6","article-title":"Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer","volume":"22","author":"Miyamoto","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R47-20230926","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1200\/JCO.2015.63.6043","article-title":"Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer","volume":"34","author":"Blauwhoff-Buskermolen","year":"2016","journal-title":"J Clin Oncol"},{"key":"R48-20230926","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jcsm.12161","article-title":"Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy","volume":"8","author":"Chu","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R49-20230926","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/jcsm.12267","article-title":"Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer","volume":"9","author":"Daly","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R50-20230926","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jcsm.12107","article-title":"Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients","volume":"7","author":"Rutten","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R51-20230926","doi-asserted-by":"crossref","first-page":"e0169136","DOI":"10.1371\/journal.pone.0169136","article-title":"Prognostic impact of CT-quantified muscle and fat distribution before and after first-line-chemotherapy in lung cancer patients","volume":"12","author":"Nattenmuller","year":"2017","journal-title":"PloS One"},{"key":"R52-20230926","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/annonc\/mdw211","article-title":"Relationship between efficacy outcomes and weight gain during treatment of advanced, nonsquamous, nonsmall-cell lung cancer patients","volume":"27","author":"Patel","year":"2016","journal-title":"Ann Oncol"},{"key":"R53-20230926","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2018.0979","article-title":"Association between changes in body composition and neoadjuvant treatment for pancreatic cancer","author":"Sandini","year":"2018","journal-title":"JAMA Surg"},{"key":"R54-20230926","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/0026-0495(95)90040-3","article-title":"Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats","volume":"44","author":"Le Bricon","year":"1995","journal-title":"Metabolism"},{"key":"R55-20230926","first-page":"490804","article-title":"Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis","volume":"2012","author":"Sultani","year":"2012","journal-title":"Chemother Res Pract"},{"key":"R56-20230926","first-page":"139","article-title":"Chemotherapy-induced muscle wasting: association with NF-kB and cancer cachexia","volume":"18","author":"Damrauer","year":"2008","journal-title":"Basic Appl Myol"},{"key":"R57-20230926","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1089\/ars.2011.3965","article-title":"Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress","volume":"15","author":"Gilliam","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"R58-20230926","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jcsm.12023","article-title":"Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved","volume":"6","author":"Chen","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R59-20230926","doi-asserted-by":"crossref","first-page":"e13604","DOI":"10.1371\/journal.pone.0013604","article-title":"Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition","volume":"5","author":"Penna","year":"2010","journal-title":"PloS One"},{"key":"R60-20230926","doi-asserted-by":"crossref","first-page":"43202","DOI":"10.18632\/oncotarget.6439","article-title":"Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations","volume":"6","author":"Pin","year":"2015","journal-title":"Oncotarget"},{"key":"R61-20230926","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3389\/fphys.2016.00472","article-title":"Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways","volume":"7","author":"Barreto","year":"2016","journal-title":"Front Physiol"},{"key":"R62-20230926","doi-asserted-by":"crossref","first-page":"32695","DOI":"10.1038\/srep32695","article-title":"Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes","volume":"6","author":"Nissinen","year":"2016","journal-title":"Sci Rep"},{"key":"R63-20230926","doi-asserted-by":"crossref","first-page":"14470","DOI":"10.1038\/s41598-017-15040-1","article-title":"ACVR2B\/Fc counteracts chemotherapy-induced loss of muscle and bone mass","volume":"7","author":"Barreto","year":"2017","journal-title":"Sci Rep"},{"key":"R64-20230926","doi-asserted-by":"crossref","first-page":"8406","DOI":"10.18632\/oncotarget.14139","article-title":"Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo","volume":"8","author":"Wright","year":"2017","journal-title":"Oncotarget"},{"key":"R65-20230926","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/en.2007-0828","article-title":"Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia","volume":"149","author":"Garcia","year":"2008","journal-title":"Endocrinology"},{"key":"R66-20230926","doi-asserted-by":"crossref","first-page":"13017","DOI":"10.1038\/s41598-017-13504-y","article-title":"Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia","volume":"7","author":"Sirago","year":"2017","journal-title":"Sci Rep"},{"key":"R67-20230926","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/jcsm.12185","article-title":"Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia","volume":"8","author":"Conte","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R68-20230926","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13395-016-0098-2","article-title":"ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anticancer treatments","volume":"6","author":"Hatakeyama","year":"2016","journal-title":"Skelet Muscle"},{"key":"R69-20230926","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.bbrc.2009.12.123","article-title":"Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia","volume":"391","author":"Benny Klimek","year":"2010","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201812000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T07:17:01Z","timestamp":1695712621000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201812000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000382","relation":{},"ISSN":["1751-4258","1751-4266"],"issn-type":[{"value":"1751-4258","type":"print"},{"value":"1751-4266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}